<DOC>
	<DOCNO>NCT00070473</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , pemetrexed disodium , use different way stop tumor cell divide stop grow die . Pemetrexed disodium may stop growth tumor cell block enzymes necessary growth . PURPOSE : This phase I trial study side effect best dose pemetrexed disodium treat young patient recurrent solid tumor .</brief_summary>
	<brief_title>Pemetrexed Disodium Treating Young Patients With Recurrent Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose pemetrexed disodium child adolescents refractory solid tumor . - Determine dose-limiting toxic effect drug patient . - Determine pharmacokinetics drug patient . Secondary - Determine , preliminarily , antitumor activity drug patient . - Correlate presence C677T polymorphism methylenetetrahydrolate reductase gene , presence polymorphism enhancer region thymidylate synthase ( TS ) gene promoter ( 2R 3R tandem repeat ) , presence polymorphism within one repeat , presence functional polymorphism 3'-untranslated region toxicity patient treated drug . - Correlate homocysteine methylmalonic acid level study entry toxicity patient treated drug . - Correlate various gene expression profile response patient treated drug . OUTLINE : This dose-escalation study . Patients receive pemetrexed disodium IV 10 minute day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos pemetrexed disodium maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 3-36 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor know curative therapy therapy know prolong survival acceptable quality life Histologic requirement waive intrinsic brain stem tumors No pleural effusion ascites Neurological deficit CNS tumor must relatively stable least 1 week prior study entry PATIENT CHARACTERISTICS : Age 1 21 Performance status Karnofsky 50100 % ( 10 year age ) Lansky 50100 % ( 10 year age ) Life expectancy At least 8 week Hematopoietic Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 ( transfusion independent ) Hemoglobin least 8.0 g/dL ( transfusion allow ) Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) ALT great 2.5 time ULN Albumin least 2 g/dL Renal Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min OR Creatinine base age follow : No great 0.8 mg/dL ( age 5 ) No great 1.0 mg/dL ( age 6 10 ) No great 1.2 mg/dL ( age 11 15 ) No great 1.5 mg/dL ( age 16 ) Pulmonary No evidence dyspnea rest No exercise intolerance Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No evidence Approvednot yet active graftversushost disease No uncontrolled infection Seizure disorder allow provide wellcontrolled anticonvulsant CNS toxicity great grade 1 PRIOR CONCURRENT THERAPY : Biologic therapy Recovered prior immunotherapy At least 7 day since prior antineoplastic biologic therapy At least 6 month since prior allogeneic stem cell transplantation More 1 week since prior growth factor No concurrent biologic therapy No concurrent immunotherapy No concurrent prophylactic growth factor support course 1 Chemotherapy No prior pemetrexed disodium More 3 week since prior myelosuppressive chemotherapy ( 4 week nitrosoureas ) recover No concurrent chemotherapy Endocrine therapy Concurrent dexamethasone CNS tumor allow provide dose stable decrease least 1 week prior study entry Radiotherapy Recovered prior radiotherapy At least 2 week since prior local palliative radiotherapy At least 6 month since prior craniospinal radiotherapy At least 6 month since prior radiotherapy 50 % pelvis At least 6 week since prior substantial bone marrow radiotherapy No concurrent radiotherapy Surgery Not specify Other No trimethoprim sulfa within 2 day study drug administration No concurrent nonsteroidal antiinflammatory agent ( e.g. , ibuprofen aspirin ) No concurrent anticancer investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>